Shopping Cart 0
Cart Subtotal
USD 0

Neuroendocrine Tumors-Pipeline Review, H1 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Neuroendocrine Tumors-Pipeline Review, H1 2017

Summary

Global Markets Direct latest Pharmaceutical and Healthcare disease pipeline guide Neuroendocrine Tumors-Pipeline Review, H1 2017, provides an overview of the Neuroendocrine Tumors (Oncology) pipeline landscape.

Neuroendocrine tumor begins in the hormone-producing cells of the body neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptom includes hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part of the body, jaundice, headache, anxiety and gastric ulcer disease. Treatments include surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct Pharmaceutical and Healthcare latest pipeline guide Neuroendocrine Tumors-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Neuroendocrine Tumors (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuroendocrine Tumors (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroendocrine Tumors and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 30, 24, 10 and 2 respectively. Similarly, the Universities portfolio in Phase II stages comprises 2 molecules, respectively.

Neuroendocrine Tumors (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroendocrine Tumors (Oncology).

The pipeline guide reviews pipeline therapeutics for Neuroendocrine Tumors (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Neuroendocrine Tumors (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Neuroendocrine Tumors (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Neuroendocrine Tumors (Oncology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Neuroendocrine Tumors (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Neuroendocrine Tumors (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 4

Neuroendocrine Tumors-Overview 5

Neuroendocrine Tumors-Therapeutics Development 6

Neuroendocrine Tumors-Therapeutics Assessment 17

Neuroendocrine Tumors-Companies Involved in Therapeutics Development 29

Neuroendocrine Tumors-Drug Profiles 52

Neuroendocrine Tumors-Dormant Projects 398

Neuroendocrine Tumors-Discontinued Products 400

Neuroendocrine Tumors-Product Development Milestones 401

Appendix 413


List Of Figure

List of Figures

Number of Products under Development for Neuroendocrine Tumors, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017


List Of Table

List of Tables

Number of Products under Development for Neuroendocrine Tumors, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Neuroendocrine Tumors-Pipeline by AbbVie Inc, H1 2017

Neuroendocrine Tumors-Pipeline by Advanced Accelerator Applications SA, H1 2017

Neuroendocrine Tumors-Pipeline by Aegis Therapeutics LLC, H1 2017

Neuroendocrine Tumors-Pipeline by Amgen Inc, H1 2017

Neuroendocrine Tumors-Pipeline by AstraZeneca Plc, H1 2017

Neuroendocrine Tumors-Pipeline by AVEO Pharmaceuticals Inc, H1 2017

Neuroendocrine Tumors-Pipeline by Boehringer Ingelheim GmbH, H1 2017

Neuroendocrine Tumors-Pipeline by Bristol-Myers Squibb Company, H1 2017

Neuroendocrine Tumors-Pipeline by Celgene Corp, H1 2017

Neuroendocrine Tumors-Pipeline by Cleave Biosciences Inc, H1 2017

Neuroendocrine Tumors-Pipeline by Crinetics Pharmaceuticals Inc, H1 2017

Neuroendocrine Tumors-Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Neuroendocrine Tumors-Pipeline by Dauntless Pharmaceuticals Inc, H1 2017

Neuroendocrine Tumors-Pipeline by DexTech Medical AB, H1 2017

Neuroendocrine Tumors-Pipeline by Eisai Co Ltd, H1 2017

Neuroendocrine Tumors-Pipeline by Eli Lilly and Company, H1 2017

Neuroendocrine Tumors-Pipeline by Esperance Pharmaceuticals Inc, H1 2017

Neuroendocrine Tumors-Pipeline by Exelixis Inc, H1 2017

Neuroendocrine Tumors-Pipeline by Foresee Pharmaceuticals LLC, H1 2017

Neuroendocrine Tumors-Pipeline by Hutchison China MediTech Ltd, H1 2017

Neuroendocrine Tumors-Pipeline by Ignyta Inc, H1 2017

Neuroendocrine Tumors-Pipeline by Ipsen SA, H1 2017

Neuroendocrine Tumors-Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017

Neuroendocrine Tumors-Pipeline by Karyopharm Therapeutics Inc, H1 2017

Neuroendocrine Tumors-Pipeline by Lexicon Pharmaceuticals Inc, H1 2017

Neuroendocrine Tumors-Pipeline by Mateon Therapeutics Inc, H1 2017

Neuroendocrine Tumors-Pipeline by Merck & Co Inc, H1 2017

Neuroendocrine Tumors-Pipeline by Midatech Pharma Plc, H1 2017

Neuroendocrine Tumors-Pipeline by Millennium Pharmaceuticals Inc, H1 2017

Neuroendocrine Tumors-Pipeline by MolMed SpA, H1 2017

Neuroendocrine Tumors-Pipeline by Northwest Biotherapeutics Inc, H1 2017

Neuroendocrine Tumors-Pipeline by Novartis AG, H1 2017

Neuroendocrine Tumors-Pipeline by OctreoPharm Sciences GmbH, H1 2017

Neuroendocrine Tumors-Pipeline by Peptron Inc, H1 2017

Neuroendocrine Tumors-Pipeline by Pfizer Inc, H1 2017

Neuroendocrine Tumors-Pipeline by Pharma Mar SA, H1 2017

Neuroendocrine Tumors-Pipeline by Progenics Pharmaceuticals Inc, H1 2017

Neuroendocrine Tumors-Pipeline by Provectus Biopharmaceuticals Inc, H1 2017

Neuroendocrine Tumors-Pipeline by Regulaxis SAS, H1 2017

Neuroendocrine Tumors-Pipeline by Strongbridge Biopharma plc, H1 2017

Neuroendocrine Tumors-Pipeline by Taiwan Liposome Company Ltd, H1 2017

Neuroendocrine Tumors-Pipeline by Tarveda Therapeutics Inc, H1 2017

Neuroendocrine Tumors-Pipeline by Threshold Pharmaceuticals Inc, H1 2017

Neuroendocrine Tumors-Pipeline by Vascular Biogenics Ltd, H1 2017

Neuroendocrine Tumors-Pipeline by Xencor Inc, H1 2017

Neuroendocrine Tumors-Dormant Projects, H1 2017

Neuroendocrine Tumors-Dormant Projects, H1 2017 (Contd..1), H1 2017

Neuroendocrine Tumors-Discontinued Products, H1 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Neuroendocrine Tumors Therapeutic Products under Development, Key Players in Neuroendocrine Tumors Therapeutics, Neuroendocrine Tumors Pipeline Overview, Neuroendocrine Tumors Pipeline, Neuroendocrine Tumors Pipeline Assessment


Companies

AbbVie Inc

Advanced Accelerator Applications SA

Aegis Therapeutics LLC

Amgen Inc

AstraZeneca Plc

AVEO Pharmaceuticals Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Celgene Corp

Cleave Biosciences Inc

Crinetics Pharmaceuticals Inc

Daiichi Sankyo Company Ltd

Dauntless Pharmaceuticals Inc

DexTech Medical AB

Eisai Co Ltd

Eli Lilly and Company

Esperance Pharmaceuticals Inc

Exelixis Inc

Foresee Pharmaceuticals LLC

Hutchison China MediTech Ltd

Ignyta Inc

Ipsen SA

Jiangsu Hengrui Medicine Co Ltd

Karyopharm Therapeutics Inc

Lexicon Pharmaceuticals Inc

Mateon Therapeutics Inc

Merck & Co Inc

Midatech Pharma Plc

Millennium Pharmaceuticals Inc

MolMed SpA

Northwest Biotherapeutics Inc

Novartis AG

OctreoPharm Sciences GmbH

Peptron Inc

Pfizer Inc

Pharma Mar SA

Progenics Pharmaceuticals Inc

Provectus Biopharmaceuticals Inc

Regulaxis SAS

Strongbridge Biopharma plc

Taiwan Liposome Company Ltd

Tarveda Therapeutics Inc

Threshold Pharmaceuticals Inc

Vascular Biogenics Ltd

Xencor Inc

Neuroendocrine Tumors-Pipeline Review, H1 2017

Summary

Global Markets Direct latest Pharmaceutical and Healthcare disease pipeline guide Neuroendocrine Tumors-Pipeline Review, H1 2017, provides an overview of the Neuroendocrine Tumors (Oncology) pipeline landscape.

Neuroendocrine tumor begins in the hormone-producing cells of the body neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptom includes hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part of the body, jaundice, headache, anxiety and gastric ulcer disease. Treatments include surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct Pharmaceutical and Healthcare latest pipeline guide Neuroendocrine Tumors-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Neuroendocrine Tumors (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuroendocrine Tumors (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroendocrine Tumors and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 30, 24, 10 and 2 respectively. Similarly, the Universities portfolio in Phase II stages comprises 2 molecules, respectively.

Neuroendocrine Tumors (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroendocrine Tumors (Oncology).

The pipeline guide reviews pipeline therapeutics for Neuroendocrine Tumors (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Neuroendocrine Tumors (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Neuroendocrine Tumors (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Neuroendocrine Tumors (Oncology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Neuroendocrine Tumors (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Neuroendocrine Tumors (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

Introduction 4

Neuroendocrine Tumors-Overview 5

Neuroendocrine Tumors-Therapeutics Development 6

Neuroendocrine Tumors-Therapeutics Assessment 17

Neuroendocrine Tumors-Companies Involved in Therapeutics Development 29

Neuroendocrine Tumors-Drug Profiles 52

Neuroendocrine Tumors-Dormant Projects 398

Neuroendocrine Tumors-Discontinued Products 400

Neuroendocrine Tumors-Product Development Milestones 401

Appendix 413


List Of Figure

List of Figures

Number of Products under Development for Neuroendocrine Tumors, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017


List Of Table

List of Tables

Number of Products under Development for Neuroendocrine Tumors, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Neuroendocrine Tumors-Pipeline by AbbVie Inc, H1 2017

Neuroendocrine Tumors-Pipeline by Advanced Accelerator Applications SA, H1 2017

Neuroendocrine Tumors-Pipeline by Aegis Therapeutics LLC, H1 2017

Neuroendocrine Tumors-Pipeline by Amgen Inc, H1 2017

Neuroendocrine Tumors-Pipeline by AstraZeneca Plc, H1 2017

Neuroendocrine Tumors-Pipeline by AVEO Pharmaceuticals Inc, H1 2017

Neuroendocrine Tumors-Pipeline by Boehringer Ingelheim GmbH, H1 2017

Neuroendocrine Tumors-Pipeline by Bristol-Myers Squibb Company, H1 2017

Neuroendocrine Tumors-Pipeline by Celgene Corp, H1 2017

Neuroendocrine Tumors-Pipeline by Cleave Biosciences Inc, H1 2017

Neuroendocrine Tumors-Pipeline by Crinetics Pharmaceuticals Inc, H1 2017

Neuroendocrine Tumors-Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Neuroendocrine Tumors-Pipeline by Dauntless Pharmaceuticals Inc, H1 2017

Neuroendocrine Tumors-Pipeline by DexTech Medical AB, H1 2017

Neuroendocrine Tumors-Pipeline by Eisai Co Ltd, H1 2017

Neuroendocrine Tumors-Pipeline by Eli Lilly and Company, H1 2017

Neuroendocrine Tumors-Pipeline by Esperance Pharmaceuticals Inc, H1 2017

Neuroendocrine Tumors-Pipeline by Exelixis Inc, H1 2017

Neuroendocrine Tumors-Pipeline by Foresee Pharmaceuticals LLC, H1 2017

Neuroendocrine Tumors-Pipeline by Hutchison China MediTech Ltd, H1 2017

Neuroendocrine Tumors-Pipeline by Ignyta Inc, H1 2017

Neuroendocrine Tumors-Pipeline by Ipsen SA, H1 2017

Neuroendocrine Tumors-Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017

Neuroendocrine Tumors-Pipeline by Karyopharm Therapeutics Inc, H1 2017

Neuroendocrine Tumors-Pipeline by Lexicon Pharmaceuticals Inc, H1 2017

Neuroendocrine Tumors-Pipeline by Mateon Therapeutics Inc, H1 2017

Neuroendocrine Tumors-Pipeline by Merck & Co Inc, H1 2017

Neuroendocrine Tumors-Pipeline by Midatech Pharma Plc, H1 2017

Neuroendocrine Tumors-Pipeline by Millennium Pharmaceuticals Inc, H1 2017

Neuroendocrine Tumors-Pipeline by MolMed SpA, H1 2017

Neuroendocrine Tumors-Pipeline by Northwest Biotherapeutics Inc, H1 2017

Neuroendocrine Tumors-Pipeline by Novartis AG, H1 2017

Neuroendocrine Tumors-Pipeline by OctreoPharm Sciences GmbH, H1 2017

Neuroendocrine Tumors-Pipeline by Peptron Inc, H1 2017

Neuroendocrine Tumors-Pipeline by Pfizer Inc, H1 2017

Neuroendocrine Tumors-Pipeline by Pharma Mar SA, H1 2017

Neuroendocrine Tumors-Pipeline by Progenics Pharmaceuticals Inc, H1 2017

Neuroendocrine Tumors-Pipeline by Provectus Biopharmaceuticals Inc, H1 2017

Neuroendocrine Tumors-Pipeline by Regulaxis SAS, H1 2017

Neuroendocrine Tumors-Pipeline by Strongbridge Biopharma plc, H1 2017

Neuroendocrine Tumors-Pipeline by Taiwan Liposome Company Ltd, H1 2017

Neuroendocrine Tumors-Pipeline by Tarveda Therapeutics Inc, H1 2017

Neuroendocrine Tumors-Pipeline by Threshold Pharmaceuticals Inc, H1 2017

Neuroendocrine Tumors-Pipeline by Vascular Biogenics Ltd, H1 2017

Neuroendocrine Tumors-Pipeline by Xencor Inc, H1 2017

Neuroendocrine Tumors-Dormant Projects, H1 2017

Neuroendocrine Tumors-Dormant Projects, H1 2017 (Contd..1), H1 2017

Neuroendocrine Tumors-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Neuroendocrine Tumors Therapeutic Products under Development, Key Players in Neuroendocrine Tumors Therapeutics, Neuroendocrine Tumors Pipeline Overview, Neuroendocrine Tumors Pipeline, Neuroendocrine Tumors Pipeline Assessment


Companies

AbbVie Inc

Advanced Accelerator Applications SA

Aegis Therapeutics LLC

Amgen Inc

AstraZeneca Plc

AVEO Pharmaceuticals Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Celgene Corp

Cleave Biosciences Inc

Crinetics Pharmaceuticals Inc

Daiichi Sankyo Company Ltd

Dauntless Pharmaceuticals Inc

DexTech Medical AB

Eisai Co Ltd

Eli Lilly and Company

Esperance Pharmaceuticals Inc

Exelixis Inc

Foresee Pharmaceuticals LLC

Hutchison China MediTech Ltd

Ignyta Inc

Ipsen SA

Jiangsu Hengrui Medicine Co Ltd

Karyopharm Therapeutics Inc

Lexicon Pharmaceuticals Inc

Mateon Therapeutics Inc

Merck & Co Inc

Midatech Pharma Plc

Millennium Pharmaceuticals Inc

MolMed SpA

Northwest Biotherapeutics Inc

Novartis AG

OctreoPharm Sciences GmbH

Peptron Inc

Pfizer Inc

Pharma Mar SA

Progenics Pharmaceuticals Inc

Provectus Biopharmaceuticals Inc

Regulaxis SAS

Strongbridge Biopharma plc

Taiwan Liposome Company Ltd

Tarveda Therapeutics Inc

Threshold Pharmaceuticals Inc

Vascular Biogenics Ltd

Xencor Inc